Strides Pharma Q3 Results: Profitability returns after a loss last year; Stock surges 5%

Share it

Strides Pharma Science is well on track to achieve the FY25 outlook of $275 million-$290 million, post-demerger.

Leave a Comment

Your email address will not be published. Required fields are marked *